Back to search
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Clinicaltrials.gov:
EU CTIS:
#2022-503042-42-00
Other:
#AC-065A203
Subscribe or share this trial
Trials at a glance
Status
Enrollment complete
Condition
Pulmonary Arterial Hypertension
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
selexipag (Uptravi)
Age
2 to 17 years old
Biological sex
All
Placebo?
No
Trial start date
July 23, 2018
Trial end date
December 31, 2026
CT.gov ID
#NCT03492177
Countries:
- Belarus,
- Belgium,
- Canada,
- China,
- France,
- Germany,
- Hungary,
- Israel,
- Malaysia,
- Poland,
- Russia,
- Serbia,
- Taiwan,
- Ukraine,
- United Kingdom,
- United States
Loading...
Saint Petersburg, Russia, 197341
Beijing, China, 100029
Montpellier, France, 34295
Montreal, Quebec, Canada, H3T 1C4
Aurora, Colorado, United States, 80045
Toulouse, France, 31059
Budapest, Hungary, 1096
London, United Kingdom, WC1N 3JH
Minsk, Belarus, 220118
Paris, France, 75015
Kuala Lumpur, Malaysia, 50400
Belgrade, Serbia, 11070
Kazan', Russia, 420059
Lviv, Ukraine, 79010
Moscow, Russia, 125412
Dnipro, Ukraine, 49070
Zaporizhzhya, Ukraine, 69063
Tainan, Taiwan, 704
Taipei, Taiwan, 100
Saint Petersburg, Russia, 194100
Samara, Russia, 443070
Kota Samarahan, Malaysia, 94300
Petach Tikvah, Israel
Kemerovo, Russia, 650002
Seattle, Washington, United States, 98105
Shanghai, China, 200127
Ramat Gan, Israel, 52621
Kiev, Ukraine, 04050
Minsk, Belarus, 220013
Ghent, Belgium, 9000
Iowa City, Iowa, United States, 52242
Freiburg im Breisgau, Germany, 70106
Belgrade, Serbia, 11000
Wroclaw, Poland, 51 124
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
